Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, S… Read more
Sanofi India Limited (SANOFI) - Net Assets
Latest net assets as of December 2025: ₹7.49 Billion INR
Based on the latest financial reports, Sanofi India Limited (SANOFI) has net assets worth ₹7.49 Billion INR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹12.55 Billion) and total liabilities (₹5.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹7.49 Billion |
| % of Total Assets | 59.71% |
| Annual Growth Rate | 2.77% |
| 5-Year Change | -66.34% |
| 10-Year Change | -56.83% |
| Growth Volatility | 15.62 |
Sanofi India Limited - Net Assets Trend (2004–2025)
This chart illustrates how Sanofi India Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sanofi India Limited (2004–2025)
The table below shows the annual net assets of Sanofi India Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₹7.49 Billion | -12.94% |
| 2024-12-31 | ₹8.61 Billion | -15.23% |
| 2023-12-31 | ₹10.15 Billion | -20.43% |
| 2022-12-31 | ₹12.76 Billion | -42.68% |
| 2021-12-31 | ₹22.26 Billion | +5.03% |
| 2020-12-31 | ₹21.19 Billion | -13.24% |
| 2019-12-31 | ₹24.42 Billion | +10.05% |
| 2018-12-31 | ₹22.19 Billion | +9.51% |
| 2017-12-31 | ₹20.26 Billion | +16.76% |
| 2016-12-31 | ₹17.36 Billion | +6.66% |
| 2015-12-31 | ₹16.27 Billion | +9.51% |
| 2014-12-31 | ₹14.86 Billion | +10.33% |
| 2013-12-31 | ₹13.47 Billion | +11.84% |
| 2012-12-31 | ₹12.04 Billion | +7.84% |
| 2011-12-31 | ₹11.17 Billion | +10.10% |
| 2010-12-31 | ₹10.14 Billion | +8.84% |
| 2009-12-31 | ₹9.32 Billion | +12.39% |
| 2008-12-31 | ₹8.29 Billion | +17.30% |
| 2007-12-31 | ₹7.07 Billion | +16.22% |
| 2006-12-31 | ₹6.08 Billion | +16.12% |
| 2005-12-31 | ₹5.24 Billion | +24.17% |
| 2004-12-31 | ₹4.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sanofi India Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹230.00 Million | 3.07% |
| Other Components | ₹7.26 Billion | 96.93% |
| Total Equity | ₹7.49 Billion | 100.00% |
Sanofi India Limited Competitors by Market Cap
The table below lists competitors of Sanofi India Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinostar Cable Co. Ltd.
SHE:300933
|
$361.36 Million |
|
Tong Ren Tang Technologies Co. Ltd
PINK:TGRNF
|
$361.38 Million |
|
Nantong Haixing Electronics Co Ltd
SHG:603115
|
$361.48 Million |
|
Fujian Yongfu Power Engineering Co Ltd Class A
SHE:300712
|
$361.49 Million |
|
Shenzhen Etmade Automatic Equipment
SHE:300812
|
$361.30 Million |
|
enCore Energy Corp.
V:EU
|
$361.16 Million |
|
Hyster-Yale Materials Handling Inc
NYSE:HY
|
$361.11 Million |
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
$361.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sanofi India Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,606,000,000 to 7,492,000,000, a change of -1,114,000,000 (-12.9%).
- Net income of 3,267,000,000 contributed positively to equity growth.
- Dividend payments of 4,422,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,898,000,000.
- Other factors increased equity by 3,939,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹3.27 Billion | +43.61% |
| Dividends Paid | ₹4.42 Billion | -59.02% |
| Other Comprehensive Income | ₹-3.90 Billion | -52.03% |
| Other Changes | ₹3.94 Billion | +52.58% |
| Total Change | ₹- | -12.94% |
Book Value vs Market Value Analysis
This analysis compares Sanofi India Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.83x to 10.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | ₹183.16 | ₹3448.30 | x |
| 2005-12-31 | ₹227.43 | ₹3448.30 | x |
| 2006-12-31 | ₹264.08 | ₹3448.30 | x |
| 2007-12-31 | ₹306.91 | ₹3448.30 | x |
| 2008-12-31 | ₹360.00 | ₹3448.30 | x |
| 2009-12-31 | ₹404.59 | ₹3448.30 | x |
| 2010-12-31 | ₹440.35 | ₹3448.30 | x |
| 2011-12-31 | ₹484.84 | ₹3448.30 | x |
| 2012-12-31 | ₹522.83 | ₹3448.30 | x |
| 2013-12-31 | ₹584.74 | ₹3448.30 | x |
| 2014-12-31 | ₹645.16 | ₹3448.30 | x |
| 2015-12-31 | ₹706.52 | ₹3448.30 | x |
| 2016-12-31 | ₹753.61 | ₹3448.30 | x |
| 2017-12-31 | ₹879.87 | ₹3448.30 | x |
| 2018-12-31 | ₹963.59 | ₹3448.30 | x |
| 2019-12-31 | ₹1060.46 | ₹3448.30 | x |
| 2020-12-31 | ₹920.08 | ₹3448.30 | x |
| 2021-12-31 | ₹966.37 | ₹3448.30 | x |
| 2022-12-31 | ₹553.96 | ₹3448.30 | x |
| 2023-12-31 | ₹440.80 | ₹3448.30 | x |
| 2024-12-31 | ₹373.68 | ₹3448.30 | x |
| 2025-12-31 | ₹325.30 | ₹3448.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sanofi India Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 43.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.78%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 1.67x
- Recent ROE (43.61%) is above the historical average (26.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 35.20% | 20.20% | 1.29x | 1.35x | ₹1.06 Billion |
| 2005 | 27.70% | 17.96% | 1.16x | 1.33x | ₹927.05 Million |
| 2006 | 27.83% | 19.15% | 1.03x | 1.41x | ₹1.08 Billion |
| 2007 | 20.43% | 16.53% | 0.95x | 1.30x | ₹737.39 Million |
| 2008 | 20.05% | 16.90% | 0.92x | 1.28x | ₹832.89 Million |
| 2009 | 16.89% | 16.15% | 0.81x | 1.29x | ₹642.35 Million |
| 2010 | 15.29% | 14.29% | 0.77x | 1.39x | ₹536.00 Million |
| 2011 | 17.12% | 15.55% | 0.82x | 1.35x | ₹795.26 Million |
| 2012 | 14.67% | 11.23% | 0.96x | 1.35x | ₹562.48 Million |
| 2013 | 19.69% | 14.66% | 0.98x | 1.37x | ₹1.31 Billion |
| 2014 | 17.74% | 13.33% | 0.89x | 1.50x | ₹1.15 Billion |
| 2015 | 19.76% | 14.66% | 0.91x | 1.48x | ₹1.59 Billion |
| 2016 | 17.53% | 12.85% | 0.93x | 1.46x | ₹1.31 Billion |
| 2017 | 16.09% | 13.23% | 0.89x | 1.37x | ₹1.23 Billion |
| 2018 | 17.15% | 13.74% | 0.93x | 1.34x | ₹1.59 Billion |
| 2019 | 16.96% | 13.49% | 0.95x | 1.33x | ₹1.70 Billion |
| 2020 | 22.54% | 16.46% | 0.99x | 1.38x | ₹2.66 Billion |
| 2021 | 42.43% | 31.94% | 0.97x | 1.38x | ₹7.22 Billion |
| 2022 | 48.64% | 22.40% | 1.34x | 1.62x | ₹4.93 Billion |
| 2023 | 59.39% | 30.20% | 1.16x | 1.69x | ₹5.01 Billion |
| 2024 | 48.02% | 20.53% | 1.25x | 1.87x | ₹3.27 Billion |
| 2025 | 43.61% | 17.78% | 1.46x | 1.67x | ₹2.52 Billion |
Industry Comparison
This section compares Sanofi India Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $4,627,121,792
- Average return on equity (ROE) among peers: 24.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sanofi India Limited (SANOFI) | ₹7.49 Billion | 35.20% | 0.67x | $361.36 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.16 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $31.83 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $405.73 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $40.08 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $823.98 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $319.07 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $159.44 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $97.10 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $30.49 Million |